Regorafenib compared to nivolumab after sorafenib failure in patients with hepatocellular carcinoma: A systematic review and meta-analysis

作者全名："Yang, Shuheng; Zhou, Yadong; Zeng, Lei"

作者地址："[Yang, Shuheng; Zhou, Yadong] Chongqing Univ, Dept Hepatobiliary Surg, Fuling Hosp, Chongqing, Peoples R China; [Zeng, Lei] Chongqing Med Univ, Dept Hepatobiliary & Pancreat Surg, Affiliated Hosp 3, Chongqing, Peoples R China"

通信作者："Zeng, L (通讯作者)，Chongqing Med Univ, Dept Hepatobiliary & Pancreat Surg, Affiliated Hosp 3, Chongqing, Peoples R China."

来源：ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE

ESI学科分类：CLINICAL MEDICINE

WOS号：WOS:001148485800002

JCR分区：Q3

影响因子：2.1

年份：2023

卷号：32

期号：8

开始页：839

结束页：845

文献类型：Review

关键词：hepatocellular carcinoma; sorafenib; regorafenib; nivolumab; meta-analysis

摘要："Which systemic therapy should be administered following sorafenib failure for patients with advanced hepatocellular carcinoma (HCC) is still a debated issue in clinical practice. This study aimed to compare regorafenib with nivolumab after sorafenib failure in patients with HCC. MEDLINE via PubMed, Scopus and Embase databases were searched for studies published until December 2021. The risk of bias (RoB) was evaluated using the Cochrane Collaboration tool for assessing risk of bias in randomized trials. From a total of 2120 articles, 3 papers were included in this meta-analysis. We found a statistically significant difference in the patient's objective response rate between the regorafenib and nivolumab groups (odds ratio (OR): 0.296, 95% confidence interval (95% CI): 0.161-0.544, p = 0.000). A statistically significant difference between regorafenib and nivolumab was not found for disease control rate after sorafenib failure in patients with advanced HCC (OR: 1.111, 95% CI: 0.793-1.557, p = 0.541) nor the number of progressive disease events (OR: 0.972, 95% CI: 0.693-1.362, p = 0.867). Overall survival (OS) and progression-free survival (PFS) were not calculable. The heterogeneity of the included data was low. Nivolumab monotherapy appears superior to regorafenib after sorafenib failure in patients with advanced HCC."

基金机构：　

基金资助正文：